Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Teva reports positive RRMS drug trial data

Teva reports positive RRMS drug trial data

16th October 2012

Teva has published new clinical trial data that demonstrates the benefits of a potential new dosing regimen of its relapsing-remitting multiple sclerosis (RRMS) therapy Copaxone.

Data from the phase III Gala trial has shown that a 40 mg/1 ml thrice-weekly regime of glatiramer acetate – the therapeutic agent used in Copaxone – helped to significantly reduce annualised relapse rates.

Moreover, reductions in new/enlarging T2 and gadolinium-enhancing (GdE) lesions in RRMS patients were also observed, as well as a favourable safety and tolerability profile.

Further analyses will continue via an open-label extension of the trial through pre-planned follow-up beyond the initial 12-month placebo-controlled phase.

Dr Michael Hayden, president of global research and development and chief scientific officer for Teva Pharmaceutical Industries, said: "We are excited about the potential to offer RRMS patients another safe and effective treatment option for this chronic and debilitating disease."

This comes after the company recently expanded its portfolio further through the acquisition of rights to an innovative new therapy for Huntington disease from NeuroSearch AS.ADNFCR-8000103-ID-801470642-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.